The “prostate cancer” pathway also comprises genes that are relatively specific to the (human) prostate (CREB3L4, KLK2, NKX3-1 and SRD5A2), proto-oncogenes (EGFR, NRAS, PDGFRA and PDGFRB), and druggable candidates (CDKN1A, CTNNB1, EGFR, NRAS, PDGFRA, PDGFRB, PIK3CD and PIK3CG) (Figure 4B, Table S1). This evidence concerns the gene CTNNB1 and prostate carcinoma.